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ABSTRACT
The G-protein-coupled receptors (GPCRs) are the largest known group of integral membrane receptor proteins
and are the most common targets of pharmacotherapy. Mast cells (MCs) have been reported to play an impor-
tant role in allergic diseases, such as urticaria and bronchial asthma. There is an increasing body of clinical evi-
dence that MCs are recruited into allergic reactions by non-IgE-dependent mechanisms. Human MCs are acti-
vated and secrete histamine in response to neuropeptides, such as substance P and somatostatin, mediated
by a GPCR, MRGX2. The microenvironment surrounding MCs in their resident tissues is likely to contain multi-
ple factors that modify antigen-dependent MC activation. MCs express various GPCRs, and since the function
of human MCs is modulated by various GPCR ligands, such as adenosine and sphingosine-1-phosphate,
which are present in high levels in the bronchial alveolar lavage fluid of asthmatic patients, the GPCRs ex-
pressed on MCs may play an important role in human allergic diseases. The GPCRs expressed on MCs may
serve as drug targets for the treatment of allergic diseases.
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INTRODUCTION
Mast cells (MCs) are known to be the primary re-
sponders in allergic reactions, most of which are trig-
gered by cross-linking of a high-affinity IgE receptor,
FcεRI. Upon activation, MCs exert their biological ef-
fects by releasing preformed and de novo-synthesized
mediators, including histamine, leukotrienes, and
various cytokineschemokines. Biogenic amines and
lipid mediators cause rapid plasma leakage from
blood vessels, vasodilation, and bronchoconstriction,
and cytokines mediate the late phase reaction charac-
terized by an inflammatory infiltrate composed of
eosinophils, basophils, neutrophils, and lympho-
cytes.1 MCs have been reported to play an important
role in allergic diseases such as urticaria and bron-
chial asthma. There is an increasing body of clinical
evidence that MCs are recruited into allergic reac-
tions by non-IgE-dependent mechanisms. Elevated
serum neuropeptide levels have been observed in pa-
tients with urticaria, and skin MCs have been found
to be activated and release histamine in response to
the neuropeptides such as substance P and somato-
statin.2,3 In this review article, we will describe the re-
lationship between the clinical evidence of involve-
ment of neuropeptides in urticaria and MC activation
through GPCRs.
MCs have been reported to express various
GPCRs on their surface, and a sub-population of
GPCRs modulates FcεRI-mediated MC activation. A
recent review by Kuehn and Gilfillan4 that thoroughly
discusses the mechanisms whereby the signaling re-
sponses utilized by FcεRI for MC activation are influ-
enced by those initiated by GPCRs to produce these
diverse responses. High levels of several GPCR
ligands, including adenosine and sphingosine-1-
phosphate (S1P), are present in the bronchial alveo-
lar lavage (BAL) fluid of asthmatic patients.5-7 In this
review article, we will next describe the relationship
between clinical evidence of involvement of GPCR
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ligands in bronchial asthma and modulation of FcεRI-
mediated MCs activation through the GPCRs.
Smooth muscle (SM) hypertrophy and hyperplasia
are now recognized as the most important factors re-
lated to airway hyperresponsiveness in vitro and in
vivo and to the severity of asthma. Many inflamma-
tory mediators and cytokines, including MC-derived
mediators, contribute to airway smooth muscle
(ASM) proliferation8 (see our review).9 Infiltration of
ASM by MCs is reported to be associated with the
impaired airway function in asthma, and the infiltra-
tion is mediated by various GPCRs expressed on
MCs. We will describe the MC expressing GPCRs
that are involved in the pathogenesis of airway re-
modeling.
The GPCRs belong to one of the largest known
group of integral membrane receptor proteins have
been exploited extensively as drug targets. For exam-
ple, adrenergic β-agonists with selectivity for the β2
adrenergic receptor, are the treatment of choice for
reversal of acute bronchospasm in bronchial asthma.
The adrenergic β-agonists inhibit FcεRI-mediated de-
granulation and cytokine production by human
MCs.10-13 Increasing evidence indicates that GPCRs
are capable of coupling to more than one G protein,
raising the possibility that different agonists can di-
rect signaling from the receptor to specific signaling
cascades as a consequence of their relative affinities
for different G-protein-coupled states of the same re-
ceptor.14 The potential for GPCRs to form complexes
with signaling proteins other than G proteins also
raises the possibility that agonists and antagonists
can discriminate between these complexes in terms
of both binding affinity and efficacy.15 Thus, each
downstream signaling pathway evaluated in a particu-
lar cell may have its own unique pharmacology de-
pending on the pathway that is stimulated by the
unique ligand-receptor conformation or complex in-
volved. In this paper, we review the involvement of
GPCRs on human MCs, but not murine MCs, in the
pathogenesis of allergic diseases.
GPCR-LIGANDS ACTIVATE HUMAN SKIN
MCs AND ARE INVOLVED IN THE PATHO-
GENESIS OF URTICARIA
A great deal of clinical evidence suggests that neu-
ropeptides play a very important role in the patho-
genesis of urticaria, angioedema, and atopic dermati-
tis. Radioimmunoassay of vasoactive intestinal
polypeptide (VIP), somatostatin, bombesin, neuro-
tensin, and β-endorphin in plasma extracts from 20
acute idiopathic urticaria patients and 20 healthy sub-
jects showed significantly lower VIP- and β-
endorphin-like values in the patients, but significantly
higher somatostatin- and bombesin-like values.2 Se-
rum substance P concentrations measured by en-
zyme immunoassay in 117 chronic ordinary urticaria
patients, 40 atopic subjects, and 24 healthy subjects
showed no significant difference in mean concentra-
tion between the chronic urticaria patients and
healthy subjects.16 However, some patients with
chronic urticaria had a very high substance P level,
suggesting that substance P does not play an impor-
tant role as a histamine-releasing factor in chronic ur-
ticaria in general but does only in occasional patients
in whom it may act as a trigger of urticaria symptoms.
The neuropeptides substance P, VIP, and somato-
statin all induce similar concentration-related release
of histamine by human skin MCs.3 The relative equi-
potency of these neuropeptides together with the ob-
servation that eledoisin, physalaemin, and neuroki-
nins A and B (NKA and NKB) induce negligible his-
tamine release strongly suggests that the activation
site for neuropeptides on human skin MCs is not any
of the classical high affinity tachykinin receptor sub-
types identified on smooth muscle. This is supported
by the observation that morphine, poly-L-lysine, and
the synthetic histamine releaser compound 4880 in-
duce histamine release in a concentration-related
manner, suggesting that the peptide sensitivity ex-
tends to other basic lipophilic substances. The pep-
tide [D-Pro4, D-Trp7,9,10] SP4-11 inhibits not only the
histamine release induced by substance P from hu-
man skin MCs in a competitive manner, but the hista-
mine release induced by VIP, somatostatin, com-
pound 4880, morphine, and poly-L-lysine, suggest-
ing that human skin MCs possess low affinity and
low-specificity activation sites for neuropeptides and
compounds with similar physicochemical properties.
In 2006, the low affinity and low-specificity activation
sites for neuropeptides and compounds were identi-
fied as a GPCR, MRG (mas-related gene) X2, al-
though whether human skin MCs express MRGX2
has not been investigated.17 The gene product of
MRG is a recently identified member of GPCRs fam-
ily. MRG consists of 32 murine and 4―7 human genes
(hMRGX1-hMRGX7).18,19 The MRG is expressed
only in a specific subset of nociceptive neurons.18,20
Human cord-blood-derived MCs express MRGX1 and
MRGX2.17 Human cord-blood-derived MCs undergo
degranulation mediated by MRGX2 in response to
substance P, VIP, somatostatin, cortistatin, indoli-
cidin, platelet factor-4, and compound 4880, how-
ever, there is still no direct evidence that these neuro-
peptides activate human skin MCs through MRGX2
and induce urticaria in vivo.
Several investigators have identified the comple-
ment anaphylatoxins C3a and C5a as potential effec-
tors in Type 1 hypersensitivity reactions, including
urticaria, rhinitis, and asthma (reviewed by Gerard
and Gerard).21 A study of sera from chronic urticaria
patients demonstrated that histamine release by ba-
sophils stimulated with patient IgG was significantly
augmented by exposure to C5a. Furthermore, deple-
tion of serum C5 or exposure to antisera against the
C5a receptor clearly implicated C5a in this reaction.22
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Table 1 GPCRs expressed on human mast cels
ReferencesMast cel responseHuman MC subtypeGPCRLigand
10,11,12,13Inhibition of FcεRI-mediated de-
granulation and cytokine production
Lung-, skin-, cord-blood-
derived, peripheral-blood-
derived
Adrenergic beta2 Adrenaline
35,36,37,38,
39,40,41,42,
43
Degranulation (low dose), inhibition 
of FcεRI-mediated degranulation 
and chemotaxis (high dose) 
Lung-Adenosine A2a, 
A2b, A3
Adenosine
23,25,26Degranulation, chemotaxis, che-
mokine secretion
Skin-, lung-, CD34＋-de-
rived, LAD2
C3aR C3a
23,24Degranulation, chemotaxisSkin-, cord-blood-derived, C5aR C5a
56Induction of migration with VIPLung-, skin-CXCR1Fractalkine
55Migration toward airway smooth 
muscle cels
Lung-CXCR3CXCL10
28DegranulationLAD2 mast cel lineGPR34Lysophosphati-
dylserine
57Enhancement of CXCL12-induced 
chemotaxis
Mast cel precursorsHistamine H4Histamine
17UnknownCord-blood-derivedMrg×1BAM
17DegranulationCord-blood-derivedMrg×2Somatostatin, 
platelet factor-
4, substance 
P, indolicidin, 
VIP, compound 
48/80
27ADP: calcium influx, eicosanoid pro-
duction, exocytosis; ATP, ADP: inhi-
bition of TLR2-mediated TNF-α, IL-
8 and MIP-1α production
Cord-blood-derivedPurinergic receptor 
P2Y1, P2Y12, P2Y13 
(ADP), P2Y2 (ATP &
UTP), P2Y11 (ATP) 
ADP, ATP & 
UTP, ATP
51Degranulation, chemotaxisCord-blood-derived, 
LAD2 mast cel line
S1P1, S1P2S1P
58,59Induction of proliferationCord-blood-derivedCysteinyl leukotriene 
receptor 1 and 2
Leukotrienes
60Acceleration of development, che-
mokine secretion
Cord-blood-derivedLPA1, LPA3Lysophosphati-
dic acid
C3a andor C5a induce degranulation, chemotaxis,
and cytokine secretion in MCs.23-26 Lysophosphatidyl-
serine, and adenine nucleotides alone have also been
reported to induce degranulaton by human MCs.27,28
However, the relationship between these GPCR
ligands and their involvement in allergic diseases is
still unclear.
THE GPCRs EXPRESSED ON HUMAN MCs
IN BRONCHIAL ASTHMA
Bronchial asthma is characterized by airway inflam-
mation, airway hyperresponsiveness, and airway re-
modeling. MCs have been reported to play an impor-
tant role in the pathogenesis of bronchial asthma
upon IgE-dependent activation. The immediate mi-
croenvironment surrounding the MCs in their resi-
dent tissues is likely to contain multiple factors that,
under certain specific conditions, modify antigen-
dependent MC activation.1,4 Several GPCR-ligands,
including adenosine and S1P, have been reported to
play an important role in asthma. The MC-GPCRs
that may be involved in the pathogenesis of allergic
diseases are summarized in Table 1. High levels of
adenosine, a metabolic by-product of ATP, are pre-
sent in exhaled breath condensates and BAL fluid
from asthmatic patients.5,6 Adenosine binds to P1
purinoceptors (purinergic receptors) and P1 purino-
ceptor subtypes A1, A2A, A2B, and A3, and binding of
adenosine to these receptors on ASM, goblet cells,
MCs, and neurons has been reported to contribute to
the pathogenesis of asthma. The MCs of allergic asth-
matics are activated after an adenosine challenge,29
and adenosine is thought to provoke bronchocon-
striction indirectly via activation of A2B adenosine re-
ceptors expressed on airway MCs.30 This was con-
firmed by measuring the blood levels of a
prostaglandin (PG) D2 metabolite 9α, 11β-PGF2, a
sensitive marker of MC activation, before and after
administering an adenosine inhalation challenge to
18 stable mild asthmatics.31 In patients with allergic
asthma in response to adenosine challenge the bron-
chial reaction was followed by an early mild but sig-
nificant (P < 0.01) mean 1.4-fold increase in plasma 9
α, 11β-PGF2 level, suggesting that MCs are involved
Okayama Y et al.
200 Allergology International Vol 57, No3, 2008 www.jsaweb.jp
in adenosine-precipitated bronchoconstriction in al-
lergic asthma but not in non-allergic asthma. How-
ever, it is still unclear whether the results reflect an
increase in the number of MCs in the airway of bron-
chial asthma patients or an increase in sensitivity of
the MCs of asthmatics to adenosine, compared to
healthy controls. By contrast, MC mediators are re-
leased in healthy subjects after an endobronchial
adenosine challenge, suggesting a dissociation be-
tween mediator release and bronchoconstriction in
response to AMP.32
A2A, A2B and A3 receptors are expressed on the sur-
face of murine MCs.33 The A2A receptor signals via
adenylate cyclase involve Gαs coupling, and the A2B
signals via multiple mechanisms including adenylate
cyclase, diacylglycerol, and inositol triphosphate, in-
volve both Gαs and Gαq coupling.34 A2B signaling has
also been shown to be mediated via PDZ-containing
proteins independently of G proteins. The effects of
adenosine on human lung MCs both in vitro and in
vivo are complex. At relatively low concentrations in
vitro (10−6 M), adenosine is said to potentiate IgE-
dependent secretion, but the reported degree of po-
tentiation has varied.35-40 Because adenosine has
been found to induce cytokine secretion by a human
MC line via the A2B receptor,41 potentiation of secre-
tion by human lung MCs is also thought to be medi-
ated via the A2B receptor, but that has not been dem-
onstrated. At higher concentrations of adenosine
(10−5 to 10−3 M), on the other hand, there is a more
consistent dose-dependent and profound inhibition of
secretion,35-37,42 mediated predominantly via the A2A
receptor.40 Adenosine has recently been shown to
dose-dependently and reversibly close K+ channel
Kca3.1 at concentrations that inhibit human lung MC
degranulation and migration (10−5 ― 10−3M). The
Kca3.1 suppression by adenosine is mediated by A2A
receptor.43
The S1P level in the BAL fluid of asthmatics in-
creases after antigen challenge, and the S1P levels in
the BAL fluid of asthmatics correlate with the eosino-
phil numbers in the BAL fluid.7 Platelets, neutrophils,
MCs, mononuclear cells, vascular endothelial cells,
and erythrocytes are able to synthesize and secrete
S1P.44-46 The cross-linking of FcεRI on rodent MCs
activates sphingosine kinase (SphK), which in turn
stimulates production of S1P.47 S1P acts as a ligand
for a family of five S1P receptors, S1P1-5, all of which
bind S1P with high affinity and specificity.48 A variety
of cells express S1P receptors, and S1P affects endo-
thelial cell function and promotes adhesion molecule
expression in endothelial cells, induces contraction
and proliferation of ASM, and fibroblast proliferation,
and shifts maturing dendritic cell-induced polariza-
tion of T cells toward a Th2 phenotype (see reviews
by Oskeritzian49 and Deshpande and Penn50). Both
S1P1 and S1P2 receptors are expressed on the surface
of MCs and S1P1 is pivotal for rodent MC chemo-
taxis. S1P2, on the other hand, mediates MC activa-
tion and degranulation.47 Since MCs secrete S1P, it is
capable of acting on its own receptors expressed on
their surface in a positive feedback loop and amplify-
ing MC function (see reviews by Oskeritzian49 and
Kuehn and Gilfillan4). In contrast to its weak effect on
degranulation of murine MCs, S1P potently induces
degranulation by human LAD2 MC line and by hu-
man cord-blood-derived MCs.51
INVOLVEMENT OF MC EXPRESSING GPCRs
IN AIRWAY REMODELING
Infiltration of ASM by MCs has been reported to be
associated with the impaired airway function ob-
served in asthma.52 Carroll et al.53 studied the num-
ber of MCs and MC degranulation in tissue obtained
at autopsies of patients who had died of asthma, pa-
tients who had asthma but died of other causes, and
non-asthmatic controls. They found that the largest
proportion of MCs was in the ASM and that the num-
ber of degranulated MCs was greatest in the patients
who had died of asthma. Increased number of intact
and degranulated MCs have been reported in ASM in
the airways of patients who died of asthma and the in-
creases were associated with a greater degree of
ASM shortening.54 These observations indicate a di-
rect interaction between MCs and ASM cells.
It has been reported that human lung MCs migrate
toward ASM in response to ASM-derived chemoki-
nes, and that CXCR3 is the most abundantly ex-
pressed chemokine receptor on human lung MCs in
ASM in asthma and is expressed by 100% of such
MCs, as compared to 47% of the MCs in the submu-
cosa.55 Human lung MC migration has been found to
be induced by ASM cultures in vitro, predominantly
through activation of CXCR3. Most importantly,
CXCL10 has been shown to be preferentially ex-
pressed by ASM in bronchial biopsy specimens and
ex vivo cells from asthmatics, compared with speci-
mens and cells from healthy control subjects. Human
ASM cells constitutively produce fractalkine, whose
synthesis increased by proinflammatory stimula-
tion.56 Under basal experimental conditions, frac-
talkine production by human ASM cells is insufficient
to induce MC chemotaxis, and exposure of MCs to
the neuropeptide VIP increases fractalkine produc-
tion to attract MCs.
It has recently been reported that histamine en-
hances CXCL12-induced chemotaxis by human MC
precursors through histamine H4 receptors.57 Since
leukotrienes and lysophosphatidic acid induce human
MC proliferation through their GPCRs,58-60 the
GPCRs expressed on human MCs may modulate air-
way remodeling in bronchial asthma. Figure 1 shows
a schematic representation of human MC-GPCR-
mediated allergic inflammation of the airways.
Mast Cell-GPCR and Allergic Diseases
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Fig. 1 Schematic representation of human MC-GPCR-mediated alergic inflammation of the airway. 
ASM, airway smooth muscle; red line, migration of human MCs toward ASM; orange line, migration of hu-
man MCs toward an alergen.
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CONCLUSIONS
In this review we have discussed how GPCRs ex-
pressed on human MCs are involved in the patho-
genesis of allergic diseases. The majority of studies of
GPCRs on MCs have been carried out on rodent
cells, but comparisons of the results obtained with
human and rodent MCs have shown significant differ-
ences in the nature of the responses generated by
GPCRs in mice and humans.4 As described above,
every GPCR-downstream signaling pathway evalu-
ated in a particular cell may have its own unique phar-
macology, depending on the pathway stimulated by
the unique ligand-receptor conformation or complex
involved. Thus, extensive studies of human MCs will
be required to exploit drugs for the treatment of hu-
man allergic diseases.
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